Compare GECC & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GECC | QNCX |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.0M | 167.0M |
| IPO Year | N/A | 2019 |
| Metric | GECC | QNCX |
|---|---|---|
| Price | $5.20 | $0.10 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $10.75 | N/A |
| AVG Volume (30 Days) | 136.6K | ★ 17.3M |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | ★ 22.35% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.92 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.63 | $0.08 |
| 52 Week High | $11.45 | $4.55 |
| Indicator | GECC | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 44.10 | 31.40 |
| Support Level | $4.63 | $0.08 |
| Resistance Level | $7.07 | $0.98 |
| Average True Range (ATR) | 0.24 | 0.01 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 68.54 | 69.76 |
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.